Professor of Cardiovascular Medicine
- Honorary Consultant Cardiologist
- Head of the Division of Cardiovascular Medicine
- Director, University of Oxford Centre Clinical Magnetic Resonance Research (OCMR)
Phenotyping of cardiovascular and multiorgan disease with advanced non-invasive imaging methods
Stefan Neubauer is a Professor of Cardiovascular Medicine, Head of the Division of Cardiovascular Medicine and Director of the Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, John Radcliffe Hospital, United Kingdom.
Professor Neubauer’s work over the past 35 years has been devoted to the development and application of Cardiovascular Magnetic Resonance (CMR) imaging and spectroscopy, and, in recent years, also to the development of novel liver and multiorgan MR imaging as well as novel coronary CT imaging.
He has attracted over £180M in research funding, has published >580 original research articles and currently leads a group of ~60 co-workers. He has supervised over 50 PhD/MD students, who have won >25 young investigator awards.
Editorial positions and contributions to scientific bodies include:
- Society for Cardiovascular Magnetic Resonance (President 2006-2007)
- Chairman of the British Society of Cardiovascular Magnetic Resonance (2008-2010)
- International Associate Editor of the European Heart Journal (2010-2020)
- Associate Editor of the Journal of Cardiovascular Magnetic Resonance.
Awards and Honours include:
- American Heart Association Paul Dudley White International Lectureship Award 2005
- British Cardiovascular Society Thomas Lewis Lecture 2008
- National Institute for Health Research Senior Investigator Award 2010
- the European Magnetic Resonance Award 2010
- the SCMR Gold Medal 2013
Professor Neubauer is a fellow of the UK Academy of Medical Sciences. He has been the leader of the Imaging Theme for the Oxford NIHR Biomedical Research Centre since 2017. He is also a founder, and was (2012-2019) CMO of Perspectum, a biomedical imaging biotech company, and is a founder and NED of Caristo Diagnostics (since 2018), a cardiac CT spinout company.
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.
Balligand J-L. et al, (2023), JAMA Cardiol, 8, 1031 - 1040
Gadolinium-free Virtual Native Enhancement for chronic myocardial infarction assessment: independent blinded validation and reproducibility between two centres
THOMPSON P. et al, (2023), Global CMR 2024 Scientific Sessions
Quality control-driven framework for reliable automated segmentation of cardiac magnetic resonance LGE and VNE images
Gonzales RA. et al, (2023)
Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M. et al, (2023), Contemp Clin Trials
Characterizing the hypertensive cardiovascular phenotype in the UK Biobank.
Elghazaly H. et al, (2023), Eur Heart J Cardiovasc Imaging, 24, 1352 - 1360
Phenotyping heart failure by cardiac magnetic resonance imaging of cardiac macro- and microscopic structure: state of the art review.
Pan J. et al, (2023), Eur Heart J Cardiovasc Imaging, 24, 1302 - 1317
Quality control-driven deep ensemble for accountable automated segmentation of cardiac magnetic resonance LGE and VNE images
Gonzales RA. et al, (2023), Frontiers in Cardiovascular Medicine
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE. et al, (2023), Lancet Gastroenterol Hepatol, 8, 704 - 713
Neuroticism personality traits are linked to adverse cardiovascular phenotypes in the UK Biobank.
Mahmood A. et al, (2023), Eur Heart J Cardiovasc Imaging
Retained Metabolic Flexibility of the Failing Human Heart.
Watson WD. et al, (2023), Circulation, 148, 109 - 123